Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
19h
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...
Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...
This acquisition marks a significant step in Jubilant Biosys' global strategy, providing a foothold in Europe's expanding ...
South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...
Jubilant Biosys Innovative Research Services Pte. Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the ...
Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd ("Kelun-Biotech" will present efficacy and safety results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback